BIOLOGICAL · Unmapped registry intervention
Rituximab
Find medicine records ·
Find other trials using this name
Clinical trial
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
NCT04121403
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Cladribine
Normalized identity: cladribineView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNorwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Relapsing Multiple Sclerosisunresolved
Multiple Sclerosisverified · MONDO: multiple sclerosis
Interventions
RituximabBIOLOGICAL
CladribineDRUG · verified · RxNorm: cladribine
Sponsors & collaborators
Oslo University Hospitallead sponsor
University of Oslocollaborator
Sykehuset Ostfoldcollaborator
Sykehuset Telemarkcollaborator
Vestre Viken Hospital Trustcollaborator
Sorlandet Hospital HFcollaborator
Helse Stavanger HFcollaborator
Sykehuset Innlandet HFcollaborator
Sykehuset i Vestfold HFcollaborator
University Hospital of North Norwaycollaborator
St. Olavs Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04121403 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.